Q3 2024 Bioventus Inc Earnings Call Transcript
Key Points
- Bioventus Inc (BVS) reported a 15% revenue growth in the third quarter, marking the fourth consecutive quarter of double-digit organic revenue growth.
- The company raised its full-year revenue guidance to the high end of previous expectations due to strong execution across all business segments.
- Surgical solutions saw accelerated double-digit growth, particularly in ultrasonics and bone graft substitutes, with strategic investments being made to further penetrate the market.
- The HA business for knee osteoarthritis delivered double-digit growth, driven by significant demand for Dura Lane, and the company is confident in sustaining above-market growth.
- Bioventus Inc (BVS) generated positive cash flow from operations in the third quarter, increased its cash position, and reduced its net leverage ratio to approximately 3.5 turns.
- The company anticipates a short-term slowdown in bone graft substitutes growth due to earlier actions to delay adding new distributors and exiting some relationships.
- There are unfavorable comps expected in Q4, particularly with Exogen, due to one-time favorability in the previous year.
- The company faces temporary lag effects in ramping up new distributors for bone graft substitutes, which may affect the start of 2025.
- Despite strong performance, adjusted gross margin was slightly down by 10 basis points compared to the previous year.
- Bioventus Inc (BVS) is facing increased pressure from competitors in the HA market, which could impact future growth.
Good day and welcome to the Bioventus third quarter, 2024 earnings conference call. (Operator Instructions) I would now like to turn the conference over to Dave Crawford. Please go ahead.
Thanks (Danielle) and Good morning, everyone and thanks for joining us. It is my pleasure to welcome you to the Bioventus 2024 3rd quarter earnings conference call with me this morning are Robert Claypoole, President, CEO and Mark Singleton, senior Vice President and CFO Robert will begin his remarks with an update on our 2024 priorities and our continued progress and Mark will provide detail of our third quarter results and discuss our updated 2024 financial guidance. We will finish the call with Q&A the presentation for today's call is available in the investors section of our website bioventus.com.
Before we begin, I would like to remind everyone that our remarks today contain forward-looking statements that are based on the current expectations of management and involve inherent risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
